Are we close to targeted treatments for Huntington’s disease? YES
Authors:
prof. MUDr. Jan Roth, CSc.
Authors‘ workplace:
1. LF UK a VFN v Praze
; Centrum extrapyramidových, onemocnění, Neurologická klinika, a Centrum klinických neurověd
Published in:
Cesk Slov Neurol N 2020; 83/116(3): 240
Category:
Controversions
Sources
-
Rodriguesa FB, Quinn L, Wild EJ. Huntington’s disease clinical trials. corner: january 2019. J Hunting Dis 2019; 8 : 115–125.
-
Smith AV, Tabrizi SJ. Therapeutic Antisense targeting of huntingtin. DNA Cell Biol 2020; 39(2): 154–158.
-
Scoles DR, Minikel EV, Pulst SM. Antisense oligonucleotides: a primer. Neurol Genet 20191; 5(2): e323.
-
Singh K, Roy I. Nucleic acid therapeutics in Huntington's disease. Recent Pat Biotechnol 2019; 13(3): 187–206.
-
Su Y, Renbao C, Huiming Y et al. CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington’s disease. J Clin Invest 2017; 127(7): 2719–2724.
-
Tabrizi SJ, Leavitt BR, Landwehrmeyer GB et al. Phase 1–2a IONIS-HTTRx study site teams. Targeting Huntingtin Expression in patients with huntington's disease. N Engl J Med 2019; 380(24): 2307–2316.
-
Zain R, Smith CI. targeted oligonucleotides for treating neurodegenerative tandem repeat diseases. Neurotherapeutics 2019; 16(2): 248–262.
Labels
Paediatric neurology Neurosurgery NeurologyArticle was published in
Czech and Slovak Neurology and Neurosurgery
2020 Issue 3
Most read in this issue
- Glioblastoma grade IV – long-term survival
- Primary progressive aphasia
- Headaches in pregnancy
- Cognitive disorders in children with epilepsy